Statins and CPAP in Adipose Tissue of OSA


About this study

This study is aimed at examining the alterations in adipose tissue in obstructive sleep apnea (OSA) patients in response to treatment with atorvastatin in continuation with standard treatment with continuous positive airway pressure (CPAP).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Participated in IRB 17-003825.
  • Apnea hypopnea index, AHI/RDI ≥ 10, or AHI/RDI > 5 with significant nocturnal hypoxemia documented by a fall in oxygen saturation to 90% or below.
  • TSH levels in range of 0.3-6 mIU/L (TSH above 6 mIU/L will be allowed if free thyroxine (free T4) is within normal range).
  • Women of child-bearing age will be allowed to participate if they agree to use acceptable birth control during the study period.

Exclusion Criteria:

  • Elevated ALT (> 3 times upper normal limit).
  • Fasting glucose > 120 mg/dL and/or  HbA1c ≥ 6.5%.
  • Females planning to be pregnant in next six months.
  • Known serious or hypersensitivity to HMG-CoA reductase inhibitors.
  • Alcohol consumption > 3 units/day.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Virend Somers, M.D., Ph.D.

Open for enrollment

Contact information:

CPL OSA Sleep Study

More information


Publications are currently not available

Mayo Clinic Footer